Regulatory Filings • Oct 7, 2008
Regulatory Filings
Open in ViewerOpens in native device viewer
_________ false
C002��� �� �� ������������� ��"�2PublicX T L BIOPHARMACEUTICALS LTD4313Corporation no: 520039470Stock Exchange/Market: ��� �� ��1996380Hasapir 3 , Nes Ziona 76100 , ,Tel: 08-9304444 , Fax: 08-9304445E.mail address: [email protected] of transmission: 07/10/2008 Time of broadcast: 14:12 14:11:27
Reference: 2008-02-281331
| Israel Securities Authority | Tel Aviv Stock Exchange | |||||
| www.isa.gov.il | www.tase.co.il |
Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
| Attached hereto is a report on Completion of the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain |
| BicifadineTrialCompletionOctober2008Final_isa.pdf |
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |
| Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD |
| Date of revision of form structure: 25/09/2008 |
| - - - |
| Name of the Signatory: : Kantor Ronen , Position of Signatory in the reporting corporation: Legal Consultant & Corporate Secretary , Name of Employer Company: . |
| Abba Hillel Silver Telephone: 03-6133371 , Facsimile: 03-6133372 , E-mail: [email protected] 2 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.